Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

OPDIVO QVANTIG

NIVOLUMAB;HYALURONIDASE-NVHY

Standard Dose
600MG;10000UNITS PER5ML(120MG/2000UNITS PER ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview OPDIVO QVANTIG is listed in Drugs@FDA under application 761381 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient NIVOLUMAB;HYALURONIDASE-NVHY Form and strength INJECTABLE;SUBCUTANEOUS - 600MG;10000UNITS PER5ML(120MG/2000UNITS PER ML) Sponsor BRISTOL-MYERS SQUIBB Submission history Latest submission status date: 2025-11-24 00:00:00.

Structured Monograph

Clinical summary

Approval overview OPDIVO QVANTIG is listed in Drugs@FDA under application 761381 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient NIVOLUMAB;HYALURONIDASE-NVHY Form and strength INJECTABLE;SUBCUTANEOUS - 600MG;10000UNITS PER5ML(120MG/2000UNITS PER ML) Sponsor BRISTOL-MYERS SQUIBB Submission history Latest submission status date: 2025-11-24 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
OPDIVO QVANTIG (NIVOLUMAB;HYALURONIDASE-NVHY) | Drug Monograph | MedicHelpline